The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are key allies in navigating costs, side effects, and long-term success. Experts like Martin Torres, PharmD, emphasize their role in maximizing benefits while minimizing risks. Here are three essential ways they support your GLP-1 experience.
US drugmaker Eli Lilly is set to bring orforglipron, a game-changing oral weight-loss pill, to India following successful global trials that included Indian patients. With obesity rates surging, this daily GLP-1 therapy promises easier access than injectables like Mounjaro. Explore the trial data, market insights, and what it means for patients.
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
Budget cuts to Medi-Cal are unraveling healthcare access for Silicon Valley's immigrant communities, leading to service delays, medication reductions, and fears of exposure. From biopsy cancellations to slashed epilepsy drug coverage, real stories reveal the strain. Nonprofits like Latinas Contra Cancer are stepping in amid a $470M Santa Clara County deficit.
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
Jelon Smart from Savannah dropped 110 pounds on Ozempic—but credits her intensive workout regimen too. Facing severe ankle swelling from Achilles tendinitis at 285 pounds, she transformed her life. Doctors remind GLP-1 users: movement and mental health are essential alongside medication.
Counterfeit versions of retatrutide, a promising but unapproved weight loss drug, are flooding online markets despite ongoing phase 3 clinical trials. Experts like obesity specialist Samantha Hocking highlight its potential for 29% body weight loss by targeting GLP-1, GIP, and glucagon. However, doctors and Eli Lilly warn of serious risks from these fake products.
